Table 2.
Treatment at the time of inclusion or at venous thromboembolism development
| Parameter | All patients (n = 187) | VTE group (n = 24) | Non-VTE group (n = 163) | P-value |
|---|---|---|---|---|
| Treatment at inclusion or onset of VTE | ||||
| Prednisolone, n (%) | 148 (79.1) | 23 (95.8) | 125 (76.7) | 0.031 |
| Prednisolone dose, mg/day, median (range) | 10 (0–80) | 15 (0–60) | 8.25 (0–80) | 0.3 |
| DMARD, n (%) | 91 (48.7) | 12 (50) | 79 (48.5) | 0.89 |
| MTX, n (%) | 32 (17.1) | 3 (12.5) | 29 (17.8) | 0.77 |
| AZA, n (%) | 35 (18.7) | 4 (16.7) | 31 (18.6) | 1.0 |
| MMF, n (%) | 24 (12.8) | 5 (20.8) | 19 (11.7) | 0.2 |
| CYC, n (%) | 50 (26.7) | 9 (3.8) | 41 (25.2) | 0.2 |
| Rituximab (within 3 months), n (%) | 6 (3.2) | 4 (16.7) | 2 (1.2) | 0.003 |
| Warfarin, n (%) | 6 (3.2) | 0 0 | 6 (3.7) | 1.0 |
| ASA, n (%) | 24 (12.8) | 4 (16.7) | 20 (12.3) | 0.52 |
| Statins, n (%) | 32 (17.1) | 3 (20.8) | 29 (17.8) | 0.77 |
| RAS blockade, any (ACEi, ARB or both), n (%) | 75 (40.1) | 7 (29.2) | 68 (41.7) | 0.27 |
| ACEi, n (%) | 50 (26.7) | 4 (16.7) | 46 (28.2) | 0.32 |
| ARB, n (%) | 30 (16.0) | 4 (16.7) | 26 (16) | 1.0 |
| Diuretics, n (%) | 41 (21.9) | 7 (29.2) | 34 (20.9) | 0.43 |
| β-Blockers, n (%) | 52 (27.8) | 4 (16.7) | 48 (29.4) | 0.23 |
| Calcium blockers, n (%) | 34 (18.2) | 1 (4.2) | 33 (20.2) | 0.08 |
Data are on the total cohort and the two patient subgroups (with or without VTE). Data on VTE patients were obtained at the time of VTE. P-values were calculated by comparing the two patient subgroups. Figures within parentheses are percentages unless stated otherwise. None remain significant after Bonferroni correction for multiple testing. ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker; RAS blockade: renin–angiotensin system blockade; VTE: venous thromboembolism.